Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Amgen's D-mab Debate
- Mike Huckman submits: Analysts are busy jawboning yesterday morning about the side effect Amgen revealed cropped up in a large, late-stage study of its bone drug known as D-mab for breast cancer patients whose disease has spread to the bones. It's known as osteonecrosis of the jaw, or ONJ,...
- External links 2009-07-09
- Merck / Cardiome: Big Pharma Meets Baby Biotech
- Mike Huckman submits: Victory for vernakalant! No, that's not German. It's the scientific, generic name of the experimental heart rhythm maintenance drug at a little Canadian company called Cardiome CRME. The announcement came out Wednesday evening that Merck MRK is hooking up with CRME in yet another...
- External links 2009-04-09
- Dendreon: Freaky Friday
- Mike Huckman submits: I'm not really enjoying my "day off" so far here in rather gloomy, cool L.A. as I've been kept pretty busy trying to chase down the Dendreon DNDN. The shares are hitting a new intra-day high on heavy volume on word that the American Urological Association...
- External links 2009-04-03
- Did Dendreon Play with Fire?
- Mike Huckman submits: Oh, the Dendreon DNDN investor message boards are on fire! And my inbox has a few sparks. Matthew Herper at Forbes wrote a piece today daring to question the integrity of the all-important data due out sometime next month on DNDN's prostate cancer treatment Provenge. Interestingly,...
- External links 2009-03-25
- Biopharma, Especially Merck, Having a Good Week
- Mike Huckman submits: Shares of Dow component Merck MRK are getting a nice little shot in the arm this morning on an upgrade by Dr. Tim Anderson at Sanford C. Bernstein. He's putting an "Outperform" or "Buy" rating on MRK and raising his target price three bucks to $30....
- External links 2009-03-13
- Will Pfizer's Pancreatic Cancer Breakthrough Help the Stock?
- Mike Huckman submits: When a press release crosses the wires or pops into the inbox from a Dow component announcing positive late-stage test results on a cancer drug, you rush to get the headlines on the air as quickly as possible. That's the nature of the TV-news biz beast....
- External links 2009-03-13
- When Will the Genentech Roller Coaster End?
- Mike Huckman submits: On my Thomson Reuters screen on the computer monitor opposite the one I'm using to write this blogpost I have the stock quotes of a few dozen of the biopharma companies I cover. Lately, when I glance over at it, there's been a lot of red....
- External links 2009-03-11
- How Can Both Genentech and Roche Rally?
- Mike Huckman submits: How can investors on both sides of the pond be reading this right? The morning after Genentech's DNA big investor meeting shares of the Swiss drugmaker Roche (RHHBY.PK) rebounded in overseas trading and the American Depository Receipts (ADR) that trade over-the-counter here in the States...
- External links 2009-03-04
- Roche Is Considerably Worse Off Without Genentech
- Mike Huckman submits: While much to my chagrin Genentech DNA isn't matching Roche's (RHHBY.PK) aggressive media strategy in the ongoing takeover battle, during parts of the biotech company's presentation to analysts and investors today, at least two executives pulled no punches. David Ebersman put up a slide titled,...
- External links 2009-03-02
- Genentech Overtakes Pfizer - Briefly
- Mike Huckman submits: As I was Googling around looking for articles to use as homework for the upcoming Genentech meeting, I stumbled across this nugget on Matthew Herper's "Science Business" blog over at "Forbes." When I wasn't looking, the market value of biotech giant Genentech DNA surpassed the market...
- External links 2009-02-28
- Pfizer: The F Is for February Failures
- Mike Huckman submits: Zero for three - that's Pfizer's PFE unfortunate drug development record this month. This morning the world's biggest pharmaceutical firm announced that it's scrapping two more drugs that were in late-stage studies. That's on top of the experimental pancreatic cancer treatment PFE gave up on...
- External links 2009-02-24
- CardioNet's Light Profit Forecast Is a Good Thing - Leerink Swann
- Mike Huckman submits: I'm a sucker for alliteration and puns. And I'm all about clever ticker symbols, provided they don't cross that fine line between clever and too cute. Genentech DNA is an example of the good kind of clever. [[WOOF]] for the animal healthcare company VCA Antech...
- External links 2009-02-19
- Pfizer / Wyeth: The Dust's Still Settling
- Mike Huckman submits: I thought the dust had pretty much settled on the Pfizer-Wyeth story. Then this morning two analysts coincidentally put out research notes on it. One of them is upgrading Pfizer PFE to the equivalent of a "Buy" rating. But the other is lowering his target price...
- External links 2009-02-12
- Biotech Analyst Eats Dendreon's Provenge Crow
- Mike Huckman submits: As late as the day before the positive Dendreon DNDN data on its prostate cancer treatment Provenge came out, biotech analyst Jonathan Aschoff at Brean Murray Carret & Co. reiterated his "Sell" rating and $1 price target on the stock in a research note to clients....
- External links 2009-04-16
- The ABCs of Lilly: Amylin, Byetta & Carl
- Mike Huckman submits: Shortly after Eli Lilly LLY reported way better than expected earnings yesterday morning, Amylin Pharmaceuticals AMLN fired a new salvo in its escalating proxy battle with billionaire activist investor Carl Icahn. LLY and AMLN are partners on the twice-a-day injectable diabetes drug Byetta, and...
- External links 2009-04-21
- Rare Failure for Roche's Avastin
- Mike Huckman submits: It's a good thing I'm working the graveyard shift this month anchoring "Worldwide Exchange" at four o'clock in the morning. It was about the time that I woke up to go to work yesterday at 1 a.m. ET that Roche (RHHBY.PK) and Genentech sent out their...
- External links 2009-04-23
- Sanofi-Aventis Stock Recovering After Lantus Leak
- Mike Huckman submits: Shares of Sanofi-Aventis SNY are getting a little investor injection on the back of the emergency release of the Lantus diabetic insulin studies late last Friday. The stock had fallen about 10 percent late last week on rumors that reports were about to be published in...
- External links 2009-06-29
- Will New CEO Be Positive for Boston Scientific?
- Mike Huckman submits: Man, it's gotta hurt when the publicly-traded company you've been leading for years announces you're stepping down and investors pop the champagne corks. Shares of several of the big medical device makers were participating in yesterday's rally, so it's hard to tell if Boston Scientific...
- External links 2009-06-26
- J&J Goes to Cougar Town
- Mike Huckman submits: This fall ABC is launching a new show with Courtney Cox called "Cougar Town." Courtney was one of my favorite "Friends" stars and cougars are certainly a hot cultural phenomenon. Could cougars be five minutes ago by the time the show premieres? Perhaps. But maybe...
- External links 2009-05-22
- Will Intuitive Surgical's Appearance on 'Grey's Anatomy' Boost Sales?
- Mike Huckman submits: Product placement in movies and TV shows has become commonplace. Usually it's a casual shot that blends into the scenery, sometimes it's a little more obvious - i.e. the Coke KO cups on the American Idol judges' desk - and occasionally it hits you in the...
- External links 2009-05-17
- << Previous
- page 1 of 3
- Next >>
Refining Tags
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
